Highlights from American Diabetes Association 2017
This years American Diabetes Association (ADA) meeting took place in San Diego, California from June 9th to June 13th. The event provides the setting for physicians, industry, and academia to come together to discuss all topics type 2 diabetes (T2D)-related. Among the announcements that were of particular interest were trial results for several current and emerging therapies.
Benefits of Novo Nordisk s Xultophy compared with basal-bolus insulin: Xultophy, a fixed dose combination (FDC) of the long-acting insulin Tresiba and the glucagon-like peptide-1 ( GLP-1 ) receptor agonist Victoza , demonstrated similar HbA1c reductions as a basal-bolus insulin regimen (insulin glargine U100 and insulin aspart), but also provided significantly lower rates of hypoglycemia and a decrease in weight. Approximately two-thirds of patients on Xultophy, reached an HbA1c target of < 7% while there was an 89% reduction in severe hypoglycemic events compared with basal-bolus insulin therapy. Furthermore, the Xultophy group required a lower daily dose of insulin versus the basal-bolus treatment arm. Xultophy is competing against Sanofis long-acting insulin/GLP-1 receptor agonist FDC Soliqua , a fusion of Lantus with Adlyxin. The widespread use of Lantus over Tresiba in the United States should result in strong physician willingness to prescribe Soliqua. However, Victozas dominance in the GLP-1 receptor agonist market, combined with its cardiovascular (CV) benefit, and the new efficacy data showcased during the ADA meeting, indicates that Soliqua will struggle to overtake Xultophy as the market Continue reading